Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents.

[1]  Simon Eckermann,et al.  The Value of Value of Information , 2012, PharmacoEconomics.

[2]  M. Sculpher,et al.  Using Value of Information Analysis to Prioritise Health Research , 2012, PharmacoEconomics.

[3]  G. Gartlehner,et al.  Comparative effectiveness reviews and the impact of funding bias. , 2010, Journal of clinical epidemiology.

[4]  Nicky J Welton,et al.  Study designs to detect sponsorship and other biases in systematic reviews. , 2010, Journal of clinical epidemiology.

[5]  C. Schmidt.  Researchers consider value-of-information theory for selecting trials. , 2010, Journal of the National Cancer Institute.

[6]  J. Ioannidis,et al.  Industry sponsorship and selection of comparators in randomized clinical trials , 2010, European journal of clinical investigation.

[7]  P. Thieda,et al.  The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. , 2010, Journal of clinical epidemiology.

[8]  John P.A. Ioannidis,et al.  Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses , 2009, Canadian Medical Association Journal.

[9]  S. Leucht,et al.  Are new drugs for schizophrenia better than old ones? – Authors' reply , 2009, The Lancet.

[10]  Are new drugs for schizophrenia better than old ones? , 2009, The Lancet.

[11]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[13]  Matthew Kowgier,et al.  Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods , 2008, Clinical trials.

[14]  John P A Ioannidis,et al.  Perfect study, poor evidence: interpretation of biases preceding study design. , 2008, Seminars in hematology.

[15]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[16]  Scott D. Ramsey,et al.  A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach , 2008, Medical care.

[17]  John Ioannidis,et al.  Exploring the Geometry of Treatment Networks , 2008, Annals of Internal Medicine.

[18]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  R. Betts,et al.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Nicky J Welton,et al.  Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses , 2007, BMJ : British Medical Journal.

[22]  R. Betts,et al.  Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.

[23]  D. Pittet,et al.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.

[24]  A. Kulkarni,et al.  Characteristics Associated with Citation Rate of the Medical Literature , 2007, PloS one.

[25]  E. Winer,et al.  Association between pharmaceutical involvement and outcomes in breast cancer clinical trials , 2007, Cancer.

[26]  G. Palit.  Correspondence - Author Reply , 2006 .

[27]  D. Skiest,et al.  A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[29]  T. Rainer,et al.  Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. , 2005, Annals of emergency medicine.

[30]  Andrew R Willan,et al.  The value of information and optimal clinical trial design , 2005, Statistics in medicine.

[31]  B. Psaty,et al.  Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis , 2004 .

[32]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[34]  T. Walsh,et al.  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  L. Stone,et al.  The checkerboard score and species distributions , 1990, Oecologia.

[36]  Yu Shen,et al.  Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction , 2003, Cancer.

[37]  C. Bagnis,et al.  Amphotericin B nephrotoxicity. , 2002, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[38]  F. Mosca,et al.  Antifungal prophylaxis in liver transplant recipients: a randomized placebo‐controlled study , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[39]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[40]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[41]  M. Spillman,et al.  Managing conflicts of interest in the conduct of clinical trials. , 2002, JAMA.

[42]  S. Pestotnik,et al.  The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. , 2001, The American journal of medicine.

[43]  D. Kontoyiannis.  A Clinical Perspective for the Management of Invasive Fungal Infections: Focus on IDSA Guidelines , 2001, Pharmacotherapy.

[44]  E. Wager,et al.  Improving the conduct and reporting of clinical trials. , 2000, JAMA.

[45]  Rennie.  Improving the conduct and reporting of clinical trials , 2000, JAMA.

[46]  D. Touw,et al.  Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial , 2000, Bone Marrow Transplantation.

[47]  D. Rennie.  Fair conduct and fair reporting of clinical trials. , 1999, JAMA.

[48]  P. Gøtzsche,et al.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.

[49]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[50]  P. Dieppe,et al.  Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? , 1993, The Lancet.

[51]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.